Trial Profile
Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Lopinavir (Primary) ; Ritonavir (Primary) ; Rabies vaccine
- Indications Hodgkin's disease; Rabies
- Focus Pharmacodynamics
- 22 May 2012 Planned End Date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 11 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Nov 2010 Actual initiation date (November 2010) added as reported by ClinicalTrials.gov.